These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 867485)
1. Tumor-associated lymphoid cells: analysis of host cells that bind to syngeneic and allogeneic tumor cells shortly after tumor administration. Schick B; Berke B Transplant Proc; 1977 Mar; 9(1):1157-60. PubMed ID: 867485 [TBL] [Abstract][Full Text] [Related]
2. Activity of tumor-associated lymphoid cells at short intervals after administration of irradiated syngeneic and allogeneic tumor cells. Schick B; Berke G J Immunol; 1977 Mar; 118(3):986-91. PubMed ID: 321684 [TBL] [Abstract][Full Text] [Related]
3. Tumor cell destruction by cytotoxic T lymphocytes: the basis of reduced antitumor cell activity in syngeneic hosts. Fishelson Z; Berke G J Immunol; 1981 May; 126(5):2048-52. PubMed ID: 6783702 [TBL] [Abstract][Full Text] [Related]
4. Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo. Truitt RL; Shih CY; Lefever AV; Tempelis LD; Andreani M; Bortin MM J Immunol; 1983 Oct; 131(4):2050-8. PubMed ID: 6194224 [TBL] [Abstract][Full Text] [Related]
5. Studies of H-2 restriction in cell-mediated cytotoxicity and transplantation immunity to Leukemia-associated antigens. Ting CC; Law LW J Immunol; 1977 Apr; 118(4):1259-64. PubMed ID: 191534 [TBL] [Abstract][Full Text] [Related]
6. Antibody-mediated suppression of grafted lymphoma. III. Evaluation of the role of thymic function, non-thymus-derived lymphocytes, macrophages, platelets, and polymorphonuclear leukocytes in syngeneic and allogeneic hosts. Shin HS; Hayden M; Langley S; Kaliss N; Smith MR J Immunol; 1975 Apr; 114(4):1255-63. PubMed ID: 1078832 [TBL] [Abstract][Full Text] [Related]
7. Resistance to tumor growth mediated by Listeria monocytogenes. Destruction of experimental malignant melanoma by LM-activated peritoneal and lymphoid cells. Youdim S J Immunol; 1976 Mar; 116(3):579-84. PubMed ID: 56396 [TBL] [Abstract][Full Text] [Related]
8. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens. Cohen P; Vourka-Karussis U; Weiss L; Slavin S J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438 [TBL] [Abstract][Full Text] [Related]
9. Humoral regulation of cell-mediated immunity to syngeneic tumor. Ting CC Cancer Res; 1976 Oct; 36(10):3695-701. PubMed ID: 953995 [TBL] [Abstract][Full Text] [Related]
10. The expression of theta-like antigen by rat peripheral lymphocytes: serologic and functional studies. Douglas TC; Dowsett AP J Immunol; 1975 Jul; 115(1):283-8. PubMed ID: 1151060 [TBL] [Abstract][Full Text] [Related]
11. Specificities of killing by cytotoxic lymphocytes generated in vivo and in vitro to syngeneic SV40 transformed cells. Gooding LR J Immunol; 1977 Mar; 118(3):920-7. PubMed ID: 191529 [TBL] [Abstract][Full Text] [Related]
12. Requirements for T cells in alloantigen-induced generation of non-T cell-mediated cytotoxicity against syngeneic mouse sarcoma cells. Paciucci PA; Macphail S; Bach FH; Zarling JM J Immunol; 1980 Jul; 125(1):36-9. PubMed ID: 6155401 [TBL] [Abstract][Full Text] [Related]
13. Recognition and response to alloantigens in vivo. I. Negative and positive selection of MLR reactivity in murine peripheral blood lymphocytes to major histocompatibility complex and Mls antigens. Ryan JJ; Ahmed A; Kind PD; Thompson CB; Berning AK; Sell KW J Immunol; 1984 Aug; 133(2):606-15. PubMed ID: 6234352 [TBL] [Abstract][Full Text] [Related]
14. Alloimmunization: induction of antileukemic reactivity without modification of anti-host reactivity in H-2-compatible mice. Truitt RL; Bortin MM; Rimm AA Transplant Proc; 1980 Mar; 12(1):143-6. PubMed ID: 6966095 [TBL] [Abstract][Full Text] [Related]
15. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments. Weiss L; Reich S; Slavin S Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572 [TBL] [Abstract][Full Text] [Related]
16. 5-halo-6-phenyl pyrimidinones: new molecules with cancer therapeutic potential and interferon-inducing capacity are strong inducers of murine natural killer cells. Lotzová E; Savary CA; Stringfellow DA J Immunol; 1983 Feb; 130(2):965-9. PubMed ID: 6848603 [TBL] [Abstract][Full Text] [Related]
17. Immunoadjuvant treatment of primary grafted and spontaneous AKR-leukemia. II. In vitro cytotoxicity of lymphoid cells against normal and malignant syngeneic cells and against normal allogeneic cells. Olsson L; Ebbesen P J Immunol; 1979 Mar; 122(3):781-6. PubMed ID: 376706 [No Abstract] [Full Text] [Related]
18. Generation of long-term T-lymphoid cell lines with specific cytotoxic reactivity for a syngeneic murine lymphoma. Eberlein TJ; Rosenstein M; Spiess PJ; Rosenberg SA J Natl Cancer Inst; 1982 Jul; 69(1):109-16. PubMed ID: 6980314 [TBL] [Abstract][Full Text] [Related]
19. Murine Pam 212 cutaneous squamous cell carcinoma is nonimmunogenic in normal syngeneic hosts and resistant to immune effector mechanisms. Chen Z; Rosten SI; Lord EM; Gaspari AA Reg Immunol; 1993; 5(5):285-92. PubMed ID: 8148238 [TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts. LeFor AT; Eisenthal A; Rosenberg SA J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]